Unilabs has licensed the rights to develop, validate, and run Natera's Panorama NIPT technology out of its own laboratories.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
Under the terms of the agreement, Natera will develop in vitro diagnostic products for oncology and pay Illumina milestone payments and royalties.
The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
The company's first quarter revenues jumped due to an increase in NIPT and carrier screening testing volumes.
The results, presented at the AACR meeting, also included data from a subset of 50 patients who have so far been tested using Natera's multiplex PCR technology.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The company's quarterly revenue of $52.9 million blew away analyst estimates and its net loss of $.47 per share was better than analysts expected.
In the pilot study, Natera's technology detected ubiquitous and heterogeneous tumor mutation variants in early-stage non-small cell lung cancer blood samples.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.